Patents Assigned to CV Therapeutics
-
Patent number: 6440948Abstract: 2-(3-,4-(substituted)-5-alkylthienyl)adenosines and the 5′-uronic acid amide analogues thereof having the following formula: are disclosed herein. Additionally disclosed are medicinal methods of treatment wherein the adenosine A2A agonist activity of the noted compounds stimulates mammalian coronary vasodilation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: June 20, 2000Date of Patent: August 27, 2002Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
-
Publication number: 20020090396Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: October 19, 2001Publication date: July 11, 2002Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John R. Langridge
-
Patent number: 6403567Abstract: 2-adenosine N-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: June 22, 1999Date of Patent: June 11, 2002Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
-
Patent number: 6369062Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: March 29, 2000Date of Patent: April 9, 2002Assignees: CV Therapeutics, Inc., Syntex (USA) Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Publication number: 20020037872Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.Type: ApplicationFiled: June 8, 2001Publication date: March 28, 2002Applicant: CV Therapeutics, Inc.Inventors: Venkata P. Palle, Jeff A. Zablocki, Prabha N. Ibrahim, Vaibhav Varkhedkar, Luiz Belardinelli
-
Publication number: 20020032327Abstract: A 2,6,9-trisubstituted purine composition that is useful for inhibiting cell proliferative disorders and as an antifungal agent.Type: ApplicationFiled: August 14, 2001Publication date: March 14, 2002Applicant: CV Therapeutics, Inc.Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow
-
Publication number: 20020004506Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: ApplicationFiled: August 9, 2001Publication date: January 10, 2002Applicant: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John R. Langridge
-
Patent number: 6303607Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: May 27, 1999Date of Patent: October 16, 2001Assignee: CV Therapeutics, Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
-
Patent number: 6294522Abstract: N6 heterocyclic 8 modified adenosine derivatives that are selective, partial or full adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.Type: GrantFiled: December 3, 1999Date of Patent: September 25, 2001Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Venkata P. Palle, Prabha N. Ibrahim, Luiz Belardenelli
-
Publication number: 20010018428Abstract: 2-adenosine C-pyrazole compositions having the following formula: 1Type: ApplicationFiled: March 19, 2001Publication date: August 30, 2001Applicant: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein
-
Patent number: 6258793Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.Type: GrantFiled: December 3, 1999Date of Patent: July 10, 2001Assignee: CV Therapeutics, Inc.Inventors: Venkata P. Palle, Jeff A. Zablocki, Prabha N. Ibrahim, Vaibhav Varkhedkar, Luiz Belardenelli
-
Patent number: 6214807Abstract: 2-adenosine C-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: June 22, 1999Date of Patent: April 10, 2001Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein
-
Patent number: 6180615Abstract: 2-adenosine propargyl phenyl ether compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: June 22, 1999Date of Patent: January 30, 2001Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein, Grigory Nudelman
-
Patent number: 6117887Abstract: This invention is novel indanone compositions useful for inhibiting cell proliferation disorders in mammals.Type: GrantFiled: June 2, 1998Date of Patent: September 12, 2000Assignee: CV Therapeutics, Inc.Inventors: Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Marek G. Nelson, Michael M. Wick
-
Patent number: 6075150Abstract: .alpha.-ketoamide compounds useful for treating disorders mediated by 20S proteasome in mammals having the following formula: wherein X.sub.2 is Ar or Ar--X.sub.3 wherein X.sub.3 is --C.dbd.O, or --CH.sub.2 CO--, and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryls; R.sub.1, and R.sub.2 are each individually selected from the side chains of the known natural .alpha.-amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and substituted heteroaryl; X.sub.1 is selected from hydroxide, monoalkylamino, dialkylamino, alkoxide, arylkoxide and ##STR1## wherein X.sub.4 is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or arylalkoxide; and R.sub.3 is selected from the known natural .alpha.Type: GrantFiled: January 26, 1998Date of Patent: June 13, 2000Assignee: CV Therapeutics, Inc.Inventors: Lisa Wang, Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Michael M Wick
-
Patent number: 5981299Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.Type: GrantFiled: July 29, 1998Date of Patent: November 9, 1999Assignee: CV Therapeutics, Inc.Inventors: Louis George Lance, III, Curtis A. Spilburg
-
Patent number: 5869537Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.Type: GrantFiled: May 9, 1997Date of Patent: February 9, 1999Assignee: CV TherapeuticsInventors: George F. Schreiner, Louis G. Lange, III
-
Patent number: 5866702Abstract: A 2,6,9-trisubstituted purine composition having the following formula: ##STR1## where X is a amino, oxo, thio, of sulfone moiety, R.sub.1 is a lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heterocycle, hetaryl, substituted hetaryl, aralkyl, heteroaralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl cycloheteroalkyl, each having from 1 to 20 carbon atoms; R.sub.2 is hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycle, hetaryl, substituted hetaryl, aralkyl, heteroaralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl cycloheteroalkyl; and R.sub.3 is halogen, hydroxyl, thio, alkoxy, alkylthio, lower alkyl, --NR.sub.4 R.sub.5 or a component having the formula: ##STR2## wherein when R.sub.3 is 2-hydroxyethylamino and R.sub.2 is methyl, R.sub.Type: GrantFiled: August 2, 1996Date of Patent: February 2, 1999Assignee: CV Therapeutics, IncorporationInventors: Richard Mackman, Robert T. Lum, Steven R. Schow, Michael M. Wick
-
Patent number: 5834487Abstract: This invention is a method for inhibiting cell proliferation using indanones.Type: GrantFiled: September 24, 1996Date of Patent: November 10, 1998Assignee: CV TherapeuticsInventors: Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Marek G. Nelson, Michael M. Wick
-
Patent number: 5789416Abstract: A substituted N.sup.6 -oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative and a method for using the composition as an A.sub.1 heart adenosine receptor.Type: GrantFiled: August 27, 1996Date of Patent: August 4, 1998Assignee: CV TherapeuticsInventors: Robert T. Lum, Jurg R. Pfister, Steven R. Schow, Michael M. Wick, Marek G. Nelson, George F. Schreiner